https://www.nasdaq.com/press-release/armata-pharmaceuticals-provides-update-on-pseudomonas-respiratory-programs-2022-01-05
https://www.nasdaq.com/press-release/armata-pharmaceuticals-provides-regulatory-and-clinical-update-reflecting-sustained
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-third-quarter-results-and-provides-general-corporate
https://www.nasdaq.com/press-release/armata-pharmaceuticals-to-present-at-the-2021-world-antimicrobial-resistance-congress
https://www.nasdaq.com/press-release/armata-enters-lease-to-build-state-of-the-art-rd-and-gmp-manufacturing-facility-2021
https://www.nasdaq.com/press-release/cystic-fibrosis-foundation-makes-equity-investment-in-armata-pharmaceuticals-2021-10
https://www.nasdaq.com/press-release/armata-pharmaceuticals-to-participate-in-the-h.c.-wainwright-23rd-annual-global
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-second-quarter-results-and-provides-general
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-chief-executive-officer-transition-2021-08-02
https://www.nasdaq.com/press-release/armata-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2021-healthcare
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-first-quarter-results-and-provides-general-corporate
https://www.nasdaq.com/press-release/innoviva-reports-first-quarter-2021-financial-results-2021-04-28
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2020-results-and
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-closing-of-second-and-final-tranche-of-%2420-million
https://www.nasdaq.com/press-release/armata-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-%2420-million-investment-to-support-advancement-of-the
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-the-addition-of-robin-c.-kramer-to-its-board-of
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-third-quarter-2020-results-and-provides-general
https://www.nasdaq.com/press-release/armata-pharmaceuticals-issues-letter-to-shareholders-2020-10-29
https://www.nasdaq.com/press-release/armata-pharmaceuticals-appoints-mina-pastagia-md-ms-as-vice-president-of-clinical
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-clearance-of-investigational-new-drug-ind
https://www.nasdaq.com/press-release/armata-pharmaceuticals-to-present-at-the-virtual-2020-world-antimicrobial-resistance
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2020
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-second-quarter-2020-results-and-provides-general
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-%2415-million-award-from-the-u.s.-department-of
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-first-quarter-2020-results-and-provides-general
https://www.nasdaq.com/press-release/armata-pharmaceuticals-to-participate-in-the-maxim-group-m-vest-infectious-disease
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-closing-of-second-tranche-of-%2425-million-securities
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2019-results-and
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-up-to-%245-million-therapeutics-development-award-from
https://www.nasdaq.com/press-release/armata-pharmaceuticals-announces-closing-of-first-tranche-of-recently-executed-%2425
https://www.nasdaq.com/press-release/armata-pharmaceuticals-and-innoviva-announce-%2425-million-strategic-investment-to
